IMMU Immunicum AB

Inbjudan till presentation av Mendus bokslutskommuniké för 2023

Inbjudan till presentation av Mendus bokslutskommuniké för 2023

Mendus AB (“Mendus” publ; IMMU. ST), publicerar sin bokslutskommuniké för 2023 onsdagen den 14 februari 2024 kl. 08:00. Bolaget kommer att hålla en webbsänd presentation kl. 10:00. Presentationen hålls av VD Erik Manting. Presentationen sker på engelska och följs av en frågestund.



Lyssna på webbsändningen av presentationen:

Vänligen skicka eventuella frågor före presentationen till



För mer information, vänligen kontakta

Erik Manting, vd

E-post:



Om Mendus AB (publ)

Mendus är dedikerade till att förändra cancerbehandlingens förlopp genom att ta itu med tumöråterfall och förbättra överlevnadsresultaten för cancerpatienter, samtidigt som livskvaliteten bevaras. Vi utnyttjar vår oöverträffade expertis inom allogen dendritcellsbiologi för att utveckla en avancerad klinisk pipeline av nya, lagringsbara, cellbaserade immunterapier som kombinerar klinisk effekt med en godartad säkerhetsprofil. Mendus är baserat i Sverige och Nederländerna och är noterat på Nasdaq Stockholm under tickern IMMU.ST.

Bilaga



EN
09/02/2024

Underlying

IMMUImmunicum AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunicum AB

Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Gross proceeds of c SEK69m to advance pipeline

Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were issued in connection with the July 2023 raise of SEK317m. Management anticipates that these proceeds will extend the cash runway to Q325 and will be applied to progress its clinical pipeline, mainly in preparation for a registrational trial for lead cancer vaccine vididencel, targeting acute myeloid leukaemia (AML) in the maintenance setting. Management expects the registrational study to commence...

04/04/24 April 4, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Regulatory green light for CADENCE trial

The Human Research Ethics Committee (HREC) has provided the green light to commence enrolment for Mendus’s AMLM22-CADENCE trial from April 2024. This Phase II trial in collaboration with the Australasian Leukaemia and Lymphoma Group, a clinical trial research group focused on haematological cancers, will evaluate lead cancer vaccine vididencel, in combination with standard of care oral azacitidine (Onureg) as a maintenance treatment for acute myeloid leukaemia (AML). A pivotal global registratio...

03/28/24 March 28, 2024 1 EN
 PRESS RELEASE
Free
IMMU IMMUNICUM AB

Mendus to present NK cell program progress at the Innate Killer Summit

Mendus to present NK cell program progress at the Innate Killer Summit Press Release Stockholm, Sweden, March 19, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present the progress of its NK cell program at the 9th Annual Innate Killer Cell Summit, a leading conference for NK cell-based therapies. Mendus Director of Research Satwinder Kaur Singh, PhD will be expert speaker at the 9th Annual Innate Killer Summit held March 18-20 in San Diego, CA, USA. The Innate Killer Summit is a lead...

March 19, 2024 1 EN
 PRESS RELEASE
Free
IMMU IMMUNICUM AB

Mendus presenterar framsteg med NK-cellsprogrammet på Innate Killer Su...

Mendus presenterar framsteg med NK-cellsprogrammet på Innate Killer Summit Pressmeddelande Stockholm den 19 mars 2024 Mendus AB (“Mendus” publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, meddelade idag att bolaget kommer att presentera utvecklingen av sitt NK-cellsprogram vid den årliga Innate Killer Cell Summit, en ledande konferens för NK-cellsbaserade terapier. Mendus forskningschef Satwinder Kaur Singh, PhD, kommer att vara experttalare på 9th Annual Innate Killer Summit som hålls den 18-20 mars i San Diego, CA, USA. Innate Killer Summit är e...

March 19, 2024 1 EN
 PRESS RELEASE
Free
IMMU IMMUNICUM AB

Mendus’ major shareholders and members of the Board of Directors and M...

Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3 Press Release Stockholm, Sweden, March 15, 2024 Mendus AB (“Mendus” or the “Company”) has received written declarations of intent whereby the Company’s major shareholders, holding approximately 65.8 percent of shares in the Company, declare their intention to exercise warrants of series TO3 (the “Warrants”) to subscribe for newly issued shares corresponding to their holdings of Warrants during the subscription period 15-29 March 2024 at the subscript...

March 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch